Replies to post #85 on Cubist Pharmaceuticals, Inc. (CBST)

[JPK1]

Surf...you still here? Interesting developements taking place with the new C-Diff tx candidate. Great potential if it pans out. I have first hand experience with C-Diff infections in the acute clinical settings and see increasing resistance to traditional therapies currently inplace. Holding LONG with this one. Also of note, some of my infectous disease specialists are transitioning to Cubacin which has shown bactericidal properties (vs bacteriostatic properties with other antibiotics) regaurding MRSA skin infections. If our tx guidelines change officially at the hospitals nationally, this will be HUGE for CBST IMHO. MRSA is rapidly becoming a pandemic, new tx guidelines for hospitalized patients that include cubicin will significantly impact shareholders positively in the near future. GLTA !